|View printer-friendly version|
|May 15, 2002 4:13 p.m.|
|Teva Announces FDA Approval of Torsemide Tablets|
Will Have 180 Days Of Marketing Exclusivity
Jerusalem, Israel, May 15, 2002 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U. S. Food and Drug Administration has issued final approval for the company's ANDA for Torsemide Tablets, 5 mg, 10 mg, 20 mg and 100 mg. This is the first approval granted by the FDA for Torsemide, and Teva will have 180 days of marketing exclusivity as the first company to file an ANDA containing a paragraph IV certification for this product. Shipments are expected to begin next month.